Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma

OBJECTIVE: Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response following neoadjuvant chemotherapy in OAC. DESIGN: Transcriptional profiling of 273 for...

Descripción completa

Detalles Bibliográficos
Autores principales: Turkington, Richard C, Knight, Laura A, Blayney, Jaine K, Secrier, Maria, Douglas, Rosalie, Parkes, Eileen E, Sutton, Eilis K, Stevenson, Leanne, McManus, Damian, Halliday, Sophia, McCavigan, Andrena M, Logan, Gemma E, Walker, Steven M, Steele, Christopher J, Perner, Juliane, Bornschein, Jan, MacRae, Shona, Miremadi, Ahmad, McCarron, Eamon, McQuaid, Stephen, Arthur, Kenneth, James, Jacqueline A, Eatock, Martin M, O’Neill, Robert, Noble, Fergus, Underwood, Timothy J, Harkin, D Paul, Salto-Tellez, Manuel, Fitzgerald, Rebecca C, Kennedy, Richard D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oesophagus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839732/
https://www.ncbi.nlm.nih.gov/pubmed/30852560
http://dx.doi.org/10.1136/gutjnl-2018-317624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839732/
https://www.ncbi.nlm.nih.gov/pubmed/30852560
http://dx.doi.org/10.1136/gutjnl-2018-317624

Ejemplares similares